Al-Wazir inaugurates glass factory, lays foundation stone for new appliance plant at Elaraby Group    New expansion projects, public-private partnerships to modernize, localise industry: El-Shimy    A blaze that exposed Egypt's fragile digital backbone    Al-Sisi attends high-level African summit to strengthen continental coordination, regional integration    Egypt, Mexico discuss environmental cooperation, combating desertification    Egypt launches anti-drug awareness campaign for drivers    Germany faces recruitment hurdles in push to rearm, eyes conscription    HDB expands national footprint with 'Acacia' branch in New Cairo    Lavrov warns against anti-Russia alliances in Asia during North Korea visit    Needle-spiking attacks in France prompt government warning, public fear    Foreign, housing ministers discuss Egypt's role in African development push    S. Korea's c. bank holds base rate at 2.50%    Egypt's annual core CPI inflation eases to 11.4% in June: CBE    Egypt's EDA, Haleon discuss local market support    Korea Culture Week in Egypt to blend K-Pop with traditional arts    Egypt, France FMs review Gaza ceasefire efforts, reconstruction    Egypt, Pakistan boost healthcare ties – Cabinet    CIB finances Giza Pyramids Sound and Light Show redevelopment with EGP 963m loan    Greco-Roman tombs with hieroglyphic inscriptions discovered in Aswan    Egypt reveals heritage e-training portal    Three ancient rock-cut tombs discovered in Aswan    Egypt condemns deadly terrorist attack in Niger        Sisi launches new support initiative for families of war, terrorism victims    Egypt's GAH, Spain's Konecta discuss digital health partnership    Egypt expands e-ticketing to 110 heritage sites, adds self-service kiosks at Saqqara    Egypt's Irrigation Minister urges scientific cooperation to tackle water scarcity    Palm Hills Squash Open debuts with 48 international stars, $250,000 prize pool    Egypt's Democratic Generation Party Evaluates 84 Candidates Ahead of Parliamentary Vote    On Sport to broadcast Pan Arab Golf Championship for Juniors and Ladies in Egypt    Golf Festival in Cairo to mark Arab Golf Federation's 50th anniversary    Germany among EU's priciest labour markets – official data    Cabinet approves establishment of national medical tourism council to boost healthcare sector    Egypt's PM follows up on Julius Nyerere dam project in Tanzania    Paris Olympic gold '24 medals hit record value    A minute of silence for Egyptian sports    Russia says it's in sync with US, China, Pakistan on Taliban    It's a bit frustrating to draw at home: Real Madrid keeper after Villarreal game    Shoukry reviews with Guterres Egypt's efforts to achieve SDGs, promote human rights    Sudan says countries must cooperate on vaccines    Johnson & Johnson: Second shot boosts antibodies and protection against COVID-19    Egypt to tax bloggers, YouTubers    Egypt's FM asserts importance of stability in Libya, holding elections as scheduled    We mustn't lose touch: Muller after Bayern win in Bundesliga    Egypt records 36 new deaths from Covid-19, highest since mid June    Egypt sells $3 bln US-dollar dominated eurobonds    Gamal Hanafy's ceramic exhibition at Gezira Arts Centre is a must go    Italian Institute Director Davide Scalmani presents activities of the Cairo Institute for ITALIANA.IT platform    







Thank you for reporting!
This image will be automatically disabled when it gets reported by several people.



AbbVie to buy Pharmacyclics for $21 billion to boost Cancer Drugs Pipeline
Published in Amwal Al Ghad on 05 - 03 - 2015

Drugmaker AbbVie Inc (ABBV.N) said it will buy Pharmacyclics Inc (PCYC.O), the maker of blockbuster cancer drug Imbruvica, for about $21 billion to broaden its oncology drugs pipeline.
The deal gives AbbVie access to Pharmacyclics' cancer drugs portfolio, lessening the Chicago-based company's dependence on its rheumatoid arthritis drug Humira that accounts for most of its sales.
The transaction follows AbbVie's failed $55 billion bid to buy Dublin-based Shire Plc (SHP.L) last October after the United States took steps to deter tax-lowering deals.
"Imbruvica is not only complementary to AbbVie's oncology pipeline, it has demonstrated strong clinical efficacy across a broad range of hematologic malignancies," AbbVie Chief Executive Richard Gonzalez said in a statement.
Pharmacyclics said earlier it expects sales of Imbruvica, which is approved in more than 40 countries and has U.S. approvals for four forms of blood cancer, to touch $1 billion in the United States this year.
AbbVie, which was spun out of Abbott Laboratories in 2013, expects the deal to be "highly accretive" to its revenue and earnings by 2017.
Sunnyvale, California-based Pharmacyclics co-markets Imbruvica with Johnson & Johnson's (JNJ.N) Janssen unit. Besides Imbruvica, it has three product candidates in development.
Media reports said Johnson & Johnson was close to buying Pharmacyclics. Novartis AG (NOVN.VX) was also interested in the company, a report said.
The acquisition is the latest in a spate of big pharma deals this year as many companies are strengthening their product offerings as old blockbuster drugs go generic. The pace of M&A is expected to continue as companies take advantage of strong capital markets.
Last month, Pfizer Inc (PFE.N) agreed to buy Hospira Inc (HSP.N) for about $15 billion, and Canada's Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N) agreed to buy Salix Pharmaceuticals Ltd (SLXP.O) for about $10.1 billion.
AbbVie will pay $261.25 per share in cash and stock, a 13 percent premium to Pharmacyclics stock's closing price on Wednesday on the Nasdaq.
The deal, expected to close in the middle of the year, comprises about 58 percent cash and 42 percent AbbVie common stock. Pharmacyclics shareholders can opt for cash, AbbVie stock or a combination, AbbVie said.
Morgan Stanley advised AbbVie, while Wachtell, Lipton, Rosen & Katz acted as legal counsel. Centerview Partners LLC and J.P. Morgan Securities were financial advisers to Pharmacyclics. Wilson Sonsini Goodrich & Rosati was its legal counsel.
Source: Reuters


Clic here to read the story from its source.